PENTAX Medical Announces Sale of C2 CryoBalloon(TM) Product Line to Merit Medical Systems through Asset Purchase Agreement
MWN-AI** Summary
PENTAX Medical, a division of the HOYA Group renowned for its flexible reusable endoscopy solutions, has announced the sale of its C2 CryoBalloon™ product line to Merit Medical Systems, Inc. This transition, formalized through an asset purchase agreement, aligns with PENTAX Medical's strategy to concentrate on its core endoscopic offerings and enhances its capability to form robust clinical partnerships.
The C2 CryoBalloon™, which has been a part of PENTAX Medical’s therapeutic line since 2017, provides a minimally invasive method for treating Barrett's Esophagus and other gastrointestinal disorders. The device employs controlled cryotherapy to ablate undesirable tissue, while preserving adjacent structures. Under Merit Medical's management, the product is expected to gain broader acceptance in the healthcare industry, increasing accessibility to treatments for patients suffering from chronic gastroesophageal reflux disease (GERD) and related conditions.
Dominique Vincent, President of PENTAX Medical, expressed pride in the clinical value C2 technology has provided and confidence that Merit Medical is well-equipped to enhance the product’s potential due to its expertise in upper gastrointestinal treatments. As part of this deal, manufacturing of the C2 CryoBalloon™ will shift to Merit Medical’s facility in South Jordan, Utah, and several employees from PENTAX will transition to merit, ensuring continuity in the development and support of the product.
This strategic decision underscores PENTAX Medical's commitment to its core mission of developing innovative, reliable endoscopic solutions that address the challenges faced by healthcare professionals globally. The collaboration with Merit Medical is expected to bolster the product's market presence while allowing PENTAX to further its focus on advancing endoscopy technologies.
MWN-AI** Analysis
The recent announcement from PENTAX Medical regarding the sale of its C2 CryoBalloon™ product line to Merit Medical Systems signals a significant strategic pivot aimed at fortifying PENTAX’s focus on core flexible reusable endoscopy. This decision aligns with broader trends in the medical device sector, where companies increasingly streamline operations to enhance specialization and operational efficiency.
From a market perspective, this acquisition is particularly noteworthy as it allows Merit Medical to deepen its offerings in the gastroenterology space, notably for patients suffering from conditions like Barrett's Esophagus and chronic GERD. The integration of C2 technology into Merit’s portfolio could enhance its competitive positioning, potentially driving revenue growth through increased adoption of the CryoBalloon™ device among healthcare providers. As PENTAX shifts focus, investors might view this as a positive move towards optimizing operational synergies and elevating their innovation game within their core competency.
PENTAX Medical’s strategy to concentrate on flexible reusable endoscopy and leverage its technological foundation could yield increased market share as healthcare systems prioritize cost-effective and reliable medical treatments. This move may also strengthen partnerships with clinical stakeholders, vital for long-term growth.
Investors should, however, remain cognizant of potential risks associated with divesting significant technology. While the sale could free up resources for PENTAX, it also reduces their therapeutic offerings, which could limit revenue streams in the short term. Conversely, Merit Medical stands to benefit from the added technology, making their stock (NASDAQ: MMSI) one to watch for potential upside as the integration unfolds.
In conclusion, both companies are poised to benefit from this transaction in different ways, but it’s critical for stakeholders to monitor the execution of integration strategies and their impact on financial performance in the upcoming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Transaction supports PENTAX Medical's strategic focus on core flexible reusable endoscopy
MONTVALE, N.J., Oct. 15, 2025 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group and a global leader in flexible reusable endoscopy, today announced an asset purchase agreement with Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, for the acquisition of the C2 CryoBalloon™ technology.
This strategic move allows PENTAX Medical to sharpen its focus on core endoscopic solutions while fostering deeper clinical partnerships.
The C2 CryoBalloon™ has been part of PENTAX Medical's therapeutic portfolio since 2017, offering a minimally invasive option to treat patients suffering from Barrett's Esophagus and other gastrointestinal disorders. The minimally invasive device delivers controlled cryotherapy to ablate unwanted tissue while preserving surrounding structures. Under Merit Medical's stewardship, the technology is expected to reach new levels of adoption and impact, expanding access to care for patients suffering from chronic GERD and related conditions.
"C2 technology has been an exciting part of our innovation journey," said Dominique Vincent, President of PENTAX Medical. "We are proud of the clinical value it has delivered and are confident that Merit Medical, with its expanding footprint in upper GI treatments and deep expertise in therapeutic endoscopy, is ideally positioned to unlock the full potential of C2. This transition allows PENTAX Medical to refocus on our core strength—flexible reusable endoscopy—and continue delivering intuitive solutions that empower clinicians worldwide."
Merit Medical will integrate the C2 CryoBalloon™ into its Endoscopy portfolio, complementing its existing products and customer base. Over the coming months, product manufacturing will be transferred to Merit's facility in South Jordan, Utah. Several PENTAX Medical employees will be joining Merit, bringing valuable expertise and continuity to the team.
The agreement reinforces PENTAX Medical's strategic focus on its core strength—flexible reusable endoscopy—and its commitment to delivering intuitive solutions that empower clinicians worldwide.
About PENTAX Medical
PENTAX Medical, a division of the HOYA Group, is a global player in flexible, reusable endoscopy solutions. The company develops, manufactures, distributes, and services endoscopic equipment worldwide. PENTAX Medical is committed to delivering intuitive, flexible endoscopy solutions that empower healthcare professionals to provide outstanding care. Its mission is to maintain product excellence while collaborating closely with clinical partners to understand and address their daily challenges, workflows, and goals. At the core of this mission is a commitment to reliability and high-quality imaging—fundamental requirements for clinical performance. Building on this foundation, PENTAX Medical delivers solutions that integrate seamlessly into clinical practice, supported by ergonomic and ease-of-use innovations, practical clinical education, and personalized, attentive customer support.
For more information, please visit our website: https://www.pentaxmedical.com.
About Merit Medical
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,300 people worldwide.
About HOYA
HOYA Corporation, founded in Tokyo in 1941, is a global leader in healthcare and technology innovation. HOYA provides advanced products for life care, including eyeglass lenses, intraocular lenses, and medical endoscopes, as well as high-precision components that support today`s information society, such as mask blanks for semiconductor manufacturing, glass substrates for hard disk drives, and optical components for imaging systems. With over 150 offices worldwide and a team of approximately 38,000 professionals, HOYA is committed to advancing technologies that contribute to a more sustainable future. For more details, please visit our website: https://www.hoya.com/en.
SOURCE PENTAX Medical
FAQ**
How will the sale of the C2 CryoBalloon™ product line to Merit Medical impact PENTAX Medical's overall strategy and focus on flexible reusable endoscopy, especially in relation to Hoya Corporation ADR HOCPY?
What benefits do PENTAX Medical anticipate from the integration of the C2 CryoBalloon™ into Merit Medical's Endoscopy portfolio, and how might this affect Hoya Corporation ADR HOCPY's market position?
Considering the transfer of manufacturing to Merit Medical's facility, what implications does this have for PENTAX Medical's operational efficiency and Hoya Corporation ADR HOCPY's supply chain dynamics?
How might the deepening clinical partnerships mentioned in the announcement enhance the competitive edge of both PENTAX Medical and Merit Medical, and what does this mean for Hoya Corporation ADR HOCPY's future growth?
**MWN-AI FAQ is based on asking OpenAI questions about Hoya Corporation ADR (OTC: HOCPY).
NASDAQ: HOCPY
HOCPY Trading
0.01% G/L:
$176.236 Last:
6,426 Volume:
$182.85 Open:
